Failure to Diagnose Prostate Cancer: A Case-Screening Guide

Cancers are one of the "Big Three" categories of serious diagnostic error. Prostate cancer is a common malignancy where the litigated failure is rarely a hidden tumor — it is an abnormal or rising PSA sitting unaddressed in the chart. The result is the same as the other delayed-cancer cases: a clue that was documented but never acted on, while a curable cancer became an incurable one.

Frequency & severity

Prostate cancer is among the most commonly diagnosed cancers in men and a leading cause of male cancer death. Many prostate cancers are indolent — which is precisely why screening and biopsy decisions are individualized and involve shared decision-making — but a meaningful subset are aggressive, and for those, delay is decisive. The harm in the litigated case is defined by stage and grade progression: a high-grade cancer that would have been localized and curable when an abnormal PSA was first ignored can metastasize to bone and become incurable over the months or years it goes unaddressed, converting a survivable diagnosis into a fatal one.

The cannot-miss clinical picture & red flags

Prostate cancer is usually asymptomatic until advanced, so the missed clue is almost always a laboratory or exam finding, not a symptom. Red flags:

• A significantly elevated PSA that was resulted but never reviewed, never communicated to the patient, or dismissed as benign without further evaluation.
• A rising PSA trend across serial tests — a clear upward trajectory (rising PSA velocity) that should prompt further evaluation rather than reassurance.
• An abnormal digital rectal exam — a nodule or asymmetry that was never worked up.
• A critically abnormal result that fell through tracking — the classic loop-closure failure, where a flagged value was never seen, communicated, or referred.
• Failure to monitor a man on active surveillance — a known low-risk cancer where a rising PSA signaling progression was not acted on.
• Higher-risk patients — family history or other risk factors that should have lowered the threshold to evaluate and refer.

The recurring standard-of-care principle: a clearly abnormal or persistently rising PSA generally warrants further evaluation — repeat or confirmatory testing, appropriate imaging, and urology referral for consideration of biopsy — and the result must be reviewed, communicated, and acted on. The breach is almost never the screening decision itself; it is the failure to act on a result that was already abnormal.

Dominant allegation types

• Failure to act on an abnormal PSA — an elevated value resulted but never reviewed, communicated, or referred.
• Failure to recognize a rising trend — serial PSAs climbing across visits with no one connecting the dots and no urology referral.
• Failure to close the loop — a critically abnormal result lost in tracking, never communicated to the patient, never followed up.
• Failure to work up an abnormal DRE — a palpable nodule documented but never evaluated.
• Failure to monitor active surveillance — progression on surveillance missed because the monitoring protocol was not followed.

What makes a strong vs. weak case

A strong case usually has a documented abnormal result, a clear failure to act, an aggressive (higher-grade) cancer, and a real stage difference:

• Breach: an abnormal or clearly rising PSA (or abnormal DRE) in the record that the standard of care required to be evaluated, communicated, and referred — and a chart showing it was not.
• Causation: proof that timely workup would more likely than not have caught the cancer when it was localized and curable rather than metastatic — or, in loss-of-chance jurisdictions, materially improved the chance of cure or survival.
• Damages: metastatic disease, more aggressive treatment, reduced survival, or death.

A weak or defensible case typically involves an indolent, low-grade cancer where the delay did not change the outcome; a documented, reasonable shared-decision-making discussion in which the patient declined screening or biopsy; PSA elevation reasonably attributed to a benign cause (BPH, prostatitis, recent instrumentation) and appropriately rechecked; or patient non-adherence — declined referral, no-showed biopsy, or refused follow-up. Because many prostate cancers are slow-growing, the causation analysis must tie the delay to a genuinely aggressive cancer and a real stage/grade shift, and a urology and oncology review of PSA kinetics and pathology is essential.

Contributing factors

Recurring factors include broken result-tracking that lets abnormal PSAs sit unreviewed; the absence of a system to flag a rising trend across separate visits; reflexive attribution of an elevated PSA to BPH without rechecking or referring; fragmented care where no provider owns the result; and, on the other side, the genuine clinical nuance of prostate-cancer screening, which can be used to justify inaction even when a result was clearly abnormal. The defensible-sounding "we don't aggressively screen" framing does not excuse ignoring a result that was already in hand.

The records angle

The chart should establish the full PSA history (every value and date, so the trend is visible), whether each result was reviewed and communicated, what the DRE showed, whether and when urology referral was made, whether any recommended biopsy or imaging was completed, and how abnormal results were tracked. A precise chronology aligning the first abnormal or rising PSA against the eventual diagnosis defines the delay interval; the PSA trend, pathology (Gleason grade), and staging anchor causation; and the EHR audit trail confirms when each result was viewed, by whom, and whether anything was amended after diagnosis.

The bottom line

The viable delayed-prostate-cancer case usually rests on an abnormal or rising PSA that was already in the chart and was never acted on — while an aggressive cancer progressed. If the record shows a result the standard of care required to be evaluated and referred, a failure to do so, and a high-grade cancer that timely action more likely than not would have caught while curable, the breach, causation, and damages can all be built from the PSA history, the pathology, and the staging data.

General information for attorneys, not legal or medical advice. Standard-of-care, causation, and damages rules vary by jurisdiction — verify every standard, statute, and deadline against current authority in your venue, and rely on a qualified medical expert for the clinical analysis.

Questions? [email protected] · (856) 979-6525